B-Cell Non-Hodgkin Lymphoma

ClinicalAugust 12, 2026

Phase I Trial of JL19001 Injection in Advanced Solid Tumors and B-NHL Initiated by Jecho Biopharmaceuticals

Jecho Biopharmaceuticals has initiated Phase I trial to evaluate JL19001 Injection in patients with advanced solid tumors and relapsed/refractory B-NHL, focusing on safety and tolerability.

Companies

Assets

Recent signals(6)

Phase I Trial of JL19001 Injection in Advanced Solid Tumors and B-NHL Initiated by Jecho Biopharmaceuticals

Mosunetuzumab shows promise in B-cell NHL beyond follicular lymphoma

AstraZeneca Initiates Phase I/II Study of AZD4512 in B-cell Non-Hodgkin Lymphoma

Epcoritamab Trial in Japanese R/R B-Cell NHL Shows Safety and Efficacy Potential

Study on CD3-CD20 Bispecific Antibody with CD19-CAR T Cells in B-NHL

Dizal Pharmaceuticals initiates trial for DZD8586 in relapsed B-cell Non-Hodgkin Lymphoma

Upcoming catalysts

Indications

Get signals before the market moves